Summary of transplantation outcomes (n = 33)
| Outcome . | Value . |
|---|---|
| Engraftment (range) | |
| Time to ANC > 500/μL, d | 14 (9-20) |
| Time to platelet > 20 000, d | 14 (10-83) |
| Acute GVHD | |
| Grade 0 | 7 (21%) |
| Grade I | 8 (24%) |
| Grade II | 9 (27%) |
| Grade III | 6 (18%) |
| Grade IV | 3 (9%) |
| GVHD time to onset, d (range) | |
| Acute > grade II | 14.5 (9-69) |
| Chronic | 190 (101-341) |
| Relapse cummulative incidence (1-y), % (95% CI) | 16% (7%-33%) |
| Survival (1-y), % (95% CI) | |
| Overall | 75% (56%-87%) |
| Event-free | 65% (46%-79%) |
| Causes of death, n (%) | |
| Respiratory failure | 1 (7%) |
| Chronic GVHD | 1 (7%) |
| Infection | 3 (21%) |
| Multiorgan failure | 2 (14%) |
| Relapse/disease progression | 7 (50%) |
| Day 100 nonrelapse cause, n (%) | |
| Infection | 2 (50%) |
| ARDS/diffuse alveolar hemorrhage | 1 (25%) |
| Multiorgan failure | 1 (25%) |
| Outcome . | Value . |
|---|---|
| Engraftment (range) | |
| Time to ANC > 500/μL, d | 14 (9-20) |
| Time to platelet > 20 000, d | 14 (10-83) |
| Acute GVHD | |
| Grade 0 | 7 (21%) |
| Grade I | 8 (24%) |
| Grade II | 9 (27%) |
| Grade III | 6 (18%) |
| Grade IV | 3 (9%) |
| GVHD time to onset, d (range) | |
| Acute > grade II | 14.5 (9-69) |
| Chronic | 190 (101-341) |
| Relapse cummulative incidence (1-y), % (95% CI) | 16% (7%-33%) |
| Survival (1-y), % (95% CI) | |
| Overall | 75% (56%-87%) |
| Event-free | 65% (46%-79%) |
| Causes of death, n (%) | |
| Respiratory failure | 1 (7%) |
| Chronic GVHD | 1 (7%) |
| Infection | 3 (21%) |
| Multiorgan failure | 2 (14%) |
| Relapse/disease progression | 7 (50%) |
| Day 100 nonrelapse cause, n (%) | |
| Infection | 2 (50%) |
| ARDS/diffuse alveolar hemorrhage | 1 (25%) |
| Multiorgan failure | 1 (25%) |
ANC indicates absolute neutrophil count; and ARDS, acute respiratory distress syndrome.